DE60040878D1 - Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und Verhaltenstörungen - Google Patents
Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und VerhaltenstörungenInfo
- Publication number
- DE60040878D1 DE60040878D1 DE60040878T DE60040878T DE60040878D1 DE 60040878 D1 DE60040878 D1 DE 60040878D1 DE 60040878 T DE60040878 T DE 60040878T DE 60040878 T DE60040878 T DE 60040878T DE 60040878 D1 DE60040878 D1 DE 60040878D1
- Authority
- DE
- Germany
- Prior art keywords
- disorders
- compositions
- treatment
- environment
- behavioral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Radiation-Therapy Devices (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14056399P | 1999-06-23 | 1999-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60040878D1 true DE60040878D1 (de) | 2009-01-02 |
Family
ID=22491816
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60040878T Expired - Lifetime DE60040878D1 (de) | 1999-06-23 | 2000-06-22 | Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und Verhaltenstörungen |
DE60019106T Expired - Lifetime DE60019106T2 (de) | 1999-06-23 | 2000-06-22 | Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60019106T Expired - Lifetime DE60019106T2 (de) | 1999-06-23 | 2000-06-22 | Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen |
Country Status (14)
Country | Link |
---|---|
US (2) | US7387778B2 (de) |
EP (2) | EP1593387B1 (de) |
JP (1) | JP2003512302A (de) |
CN (1) | CN1189211C (de) |
AT (2) | ATE414529T1 (de) |
AU (1) | AU6154700A (de) |
CA (1) | CA2376935A1 (de) |
CY (1) | CY1108745T1 (de) |
DE (2) | DE60040878D1 (de) |
DK (2) | DK1185294T3 (de) |
ES (2) | ES2238299T3 (de) |
NZ (1) | NZ516477A (de) |
PT (2) | PT1185294E (de) |
WO (1) | WO2001000221A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
DK1185294T3 (da) | 1999-06-23 | 2005-08-01 | Centre Nat Rech Scient | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
DK1216707T3 (da) * | 2000-12-22 | 2005-05-09 | Pasteur Institut | Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet |
ATE365174T1 (de) | 2003-01-28 | 2007-07-15 | Microbia Inc | Zusammensetzungen zur behandlung von gastrointestinalen störungen |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
ES2390075T3 (es) | 2004-03-19 | 2012-11-06 | Institut Pasteur | Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2688161C (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
SI2274321T1 (sl) | 2008-04-07 | 2019-04-30 | Institut Pasteur | Opiorfinski peptidni derivati kot učinkoviti inhibitorji enkefalin-degradirajočih ektopeptidaz |
FR2931362B1 (fr) | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
CA2645452A1 (en) * | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
EP2373296B1 (de) | 2008-12-03 | 2016-08-03 | Synergy Pharmaceuticals Inc. | Formulierungen von guanylatcyclase-c-agonisten und anwendungsverfahren |
DE102009039655B3 (de) | 2009-09-02 | 2011-03-31 | ITT Mfg. Enterprises, Inc., Wilmington | UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
EP2970384A1 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonisten der guanylatcyclase und deren verwendungen |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
GB201607814D0 (en) | 2016-05-04 | 2016-06-15 | 5D Health Prot Group Ltd | Anti-microbial compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8327966D0 (en) * | 1983-10-19 | 1983-11-23 | Nyegaard & Co As | Chemical compounds |
FR2637600B1 (fr) * | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
US5589189A (en) * | 1994-09-14 | 1996-12-31 | Nexstar Pharmaceuticals, Inc. | Liposome dispersion |
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
US6455564B1 (en) * | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
DK1185294T3 (da) | 1999-06-23 | 2005-08-01 | Centre Nat Rech Scient | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
DK1216707T3 (da) | 2000-12-22 | 2005-05-09 | Pasteur Institut | Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet |
-
2000
- 2000-06-22 DK DK00947924T patent/DK1185294T3/da active
- 2000-06-22 WO PCT/EP2000/006259 patent/WO2001000221A2/en active IP Right Grant
- 2000-06-22 NZ NZ516477A patent/NZ516477A/xx not_active IP Right Cessation
- 2000-06-22 EP EP05006494A patent/EP1593387B1/de not_active Expired - Lifetime
- 2000-06-22 JP JP2001505930A patent/JP2003512302A/ja active Pending
- 2000-06-22 AU AU61547/00A patent/AU6154700A/en not_active Abandoned
- 2000-06-22 EP EP00947924A patent/EP1185294B1/de not_active Expired - Lifetime
- 2000-06-22 PT PT00947924T patent/PT1185294E/pt unknown
- 2000-06-22 DE DE60040878T patent/DE60040878D1/de not_active Expired - Lifetime
- 2000-06-22 ES ES00947924T patent/ES2238299T3/es not_active Expired - Lifetime
- 2000-06-22 CN CNB008092958A patent/CN1189211C/zh not_active Expired - Fee Related
- 2000-06-22 DK DK05006494T patent/DK1593387T3/da active
- 2000-06-22 DE DE60019106T patent/DE60019106T2/de not_active Expired - Lifetime
- 2000-06-22 AT AT05006494T patent/ATE414529T1/de active
- 2000-06-22 PT PT05006494T patent/PT1593387E/pt unknown
- 2000-06-22 ES ES05006494T patent/ES2315753T3/es not_active Expired - Lifetime
- 2000-06-22 CA CA002376935A patent/CA2376935A1/en not_active Abandoned
- 2000-06-22 AT AT00947924T patent/ATE291927T1/de active
-
2001
- 2001-12-21 US US10/024,535 patent/US7387778B2/en not_active Expired - Fee Related
-
2002
- 2002-12-10 US US10/315,445 patent/US20030186870A1/en not_active Abandoned
-
2009
- 2009-01-16 CY CY20091100058T patent/CY1108745T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT1185294E (pt) | 2005-08-31 |
WO2001000221A2 (en) | 2001-01-04 |
AU6154700A (en) | 2001-01-31 |
WO2001000221A3 (en) | 2001-05-03 |
EP1185294A2 (de) | 2002-03-13 |
NZ516477A (en) | 2004-02-27 |
US20030186870A1 (en) | 2003-10-02 |
JP2003512302A (ja) | 2003-04-02 |
PT1593387E (pt) | 2009-03-18 |
DE60019106T2 (de) | 2006-02-16 |
EP1185294B1 (de) | 2005-03-30 |
CY1108745T1 (el) | 2014-04-09 |
ES2238299T3 (es) | 2005-09-01 |
US7387778B2 (en) | 2008-06-17 |
EP1593387B1 (de) | 2008-11-19 |
ATE291927T1 (de) | 2005-04-15 |
DE60019106D1 (de) | 2005-05-04 |
EP1593387A1 (de) | 2005-11-09 |
CN1189211C (zh) | 2005-02-16 |
CN1356906A (zh) | 2002-07-03 |
DK1593387T3 (da) | 2009-03-02 |
US20030078200A1 (en) | 2003-04-24 |
ES2315753T3 (es) | 2009-04-01 |
DK1185294T3 (da) | 2005-08-01 |
CA2376935A1 (en) | 2001-01-04 |
ATE414529T1 (de) | 2008-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108745T1 (el) | Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων | |
ATE430193T1 (de) | Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
ATE510542T1 (de) | Noribogain zur behandlung von schmerzen und drogenabhängigkeit | |
DE60233805D1 (de) | Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen | |
ATE319453T1 (de) | Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
HK1080467B (zh) | 用於治療過度增生疾病的苯並呋喃和苯並噻吩衍生物 | |
ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
ATE477811T1 (de) | Oxytocin zur behandlung von autismus und asperger-syndrom | |
WO2005020928A3 (en) | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins | |
DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
BR0015698A (pt) | Composições e métodos para tratamento de doenças alérgicas | |
DE69905878T2 (de) | Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen | |
ATE296098T1 (de) | Verwendung von topiramat zur behandlung und diagnostizierung von atemstörungen während des schlafens und mittel zur durchführung der behandlung und diagnose | |
ATE355054T1 (de) | Verfahren und verbindungen zur behandlung der depression | |
ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
MXPA06014182A (es) | Nucleosidos de 3-??-d-ribofuranosiltiazolo[4,5-d]piridimina y usos de los mismos. | |
DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
MXPA04010816A (es) | Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. | |
ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
ATE498397T1 (de) | Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen | |
DE60108241D1 (de) | Felabamat-derivate zur behandlung von neuropathischem schmerz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |